- French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide
- Mometasone Sandoz® is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler
- Allergic rhinitis affects up to 25% of the population of Western Europe annually
Levallois-Perret, June 2, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, …